Christopher K. Mutz serves as the Senior Vice President and Head of Rare Disease at ANI Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In his role, Mutz is responsible for overseeing the strategic direction and growth of ANI's rare disease portfolio, which aims to address the unique needs of patients with rare and orphan diseases. Mutz brings a wealth of experience in the pharmaceutical industry, particularly in the rare disease and specialty therapeutics space. Prior to joining ANI Pharmaceuticals, he held various leadership positions at notable companies such as Retrophin, where he served as Vice President of Global Market Access and Commercial Operations. During his tenure at Retrophin, Mutz played a key role in the successful launch and commercialization of several rare disease therapies, demonstrating his ability to navigate the complex landscape of rare disease drug development and market access. Throughout his career, Mutz has been recognized for his strategic vision, operational expertise, and commitment to improving the lives of patients with rare diseases. His leadership at ANI Pharmaceuticals is focused on driving innovation, fostering collaborations, and expanding the company's rare disease pipeline to bring much-needed treatments to underserved patient populations. With his extensive experience and dedication to the rare disease community, Mutz is well-positioned to guide ANI Pharmaceuticals in its mission to make a meaningful impact in the lives of patients with rare and orphan diseases.